List of Excipients in Branded Drug VINCASAR PFS

Generic Drugs Containing VINCASAR PFS

Company	Ingredient	NDC	Excipient
Teva Parenteral Medicines Inc	vincristine sulfate	0703-4402	ACETIC ACID
Teva Parenteral Medicines Inc	vincristine sulfate	0703-4402	MANNITOL
Teva Parenteral Medicines Inc	vincristine sulfate	0703-4402	SODIUM ACETATE ANHYDROUS
Teva Parenteral Medicines Inc	vincristine sulfate	0703-4402	WATER

What are the Most Frequently-Used Excipients in VINCASAR PFS?

# Of NDCs	Excipient
1	ACETIC ACID
1	MANNITOL
1	SODIUM ACETATE ANHYDROUS
1	WATER

Vincasar PFS Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Vincasar PFS is a preservative-free, ready-to-use vincristine sulfate injection supplied for intravenous administration. Its current excipient profile is intentionally narrow: sodium chloride in water for injection, with pH adjustment using hydrochloric acid and/or sodium hydroxide. The commercial opportunity is therefore not a complex formulation redesign. It is a delivery, handling, packaging, and supply-chain strategy built around medication-error prevention, aseptic workflow, dose standardization, and reliable oncology distribution.

Vincasar PFS has limited traditional pharmaceutical exclusivity. Vincristine sulfate is an established cytotoxic drug with generic injectable competition, no meaningful biosimilar pathway, and no clear dependence on a contemporary composition-of-matter patent. Product differentiation depends on presentation and hospital economics rather than chemical novelty.

What is the formulation of Vincasar PFS?

Vincasar PFS contains vincristine sulfate at a nominal concentration of 1 mg/mL for intravenous use. The product is preservative-free and supplied as a ready-to-use parenteral presentation.

Formulation element	Vincasar PFS profile	Commercial implication
Active ingredient	Vincristine sulfate	Established cytotoxic oncology drug
Concentration	1 mg/mL	Supports dose calculation and standardized preparation
Primary solvent	Water for injection	Conventional parenteral vehicle
Tonicity agent	Sodium chloride	Supports a near-isotonic injectable formulation
pH adjustment	Hydrochloric acid and/or sodium hydroxide, according to product labeling	Enables pH control without adding functional excipients
Preservative	None	Appropriate for a single-dose oncology product and reduces preservative exposure
Route	Intravenous only	Requires strict labeling and administration controls
Presentation	Ready-to-use prefilled syringe format	Reduces pharmacy compounding steps and preparation-related exposure

The FDA labeling carries a prominent warning that vincristine is for intravenous use only. Accidental intrathecal administration is generally fatal. The ready-to-use presentation therefore has a safety value beyond convenience: it can reduce the number of manipulation steps and reinforce route-specific handling controls.[1]

Why does Vincasar PFS use a minimal excipient system?

The excipient strategy reflects the constraints of a highly potent cytotoxic injectable.

A minimal formulation reduces the number of variables affecting chemical stability, container compatibility, particulate formation, and toxicology. Sodium chloride provides tonicity adjustment while water for injection supplies the parenteral vehicle. pH adjustment enables control of the solution environment without introducing additional functional excipients.

Preservatives are commercially unattractive in this setting. Vincristine is administered in oncology facilities that generally use single-dose containers and controlled aseptic preparation. A preservative could create compatibility, toxicity, or regulatory questions without adding substantial clinical value.

The formulation also supports a straightforward regulatory story. Any new excipient would require an assessment of:

• chemical compatibility with vincristine sulfate;
• adsorption to syringe and tubing materials;
• extractables and leachables;
• photostability;
• particulate generation;
• container-closure integrity;
• sterilization and aseptic processing;
• compatibility with infusion fluids;
• occupational exposure controls.

For a mature generic oncology product, these development costs are difficult to justify unless the excipient materially improves shelf life, administration safety, or manufacturing economics.

What excipient opportunities exist for Vincasar PFS?

The strongest opportunities are in packaging and administration rather than in adding new solution excipients.

1. Prefilled syringe optimization

The prefilled syringe is the main commercial platform. Development priorities include:

• low-sorption syringe components;
• reliable plunger glide force;
• tamper-evident packaging;
• clear dose and route labeling;
• needle-free connectivity;
• compatibility with closed-system transfer devices;
• reduced dead volume;
• automated barcode verification;
• protection from light during storage and use.

A low-dead-volume syringe can reduce residual drug loss, which matters for an expensive cytotoxic agent and for weight-based dosing. The commercial value is strongest where hospitals use dose banding or prepare many individualized oncology doses.

2. Ready-to-administer dose configurations

The nominal 1 mg/mL concentration permits multiple dose presentations. A supplier could develop standardized configurations such as 1 mg, 2 mg, or other institutionally relevant fill volumes, subject to regulatory and manufacturing validation.

The opportunity is not simply to offer more sizes. Excessive SKU proliferation increases inventory complexity and expiry risk. A commercially viable portfolio should match common adult and pediatric dosing patterns while preserving a simple stocking model.

3. Closed-system compatibility

Hospitals increasingly use closed-system drug-transfer devices and hazardous-drug handling systems. A Vincasar PFS-compatible syringe and connector system could create differentiation if it:

• reduces transfer steps;
• limits aerosol or vapor escape;
• fits standard oncology pharmacy equipment;
• maintains container-closure integrity;
• supports traceable administration records.

Compatibility claims require testing with the specific device, connector, infusion line, and transfer workflow. General compatibility language would have limited commercial value.

4. Light-protective packaging

Vincristine injectable products are commonly handled with light-protection requirements. A packaging platform using an opaque blister, amber overwrap, or light-protective secondary pouch could reduce handling errors while preserving the product’s existing solution formulation.

This is a lower-risk development pathway than changing the aqueous vehicle. The value is strongest if the package also supports barcode scanning and clear differentiation from other vinca alkaloids.

5. Stability extension

A longer shelf life or greater in-use stability could reduce oncology pharmacy waste. The main development variables would include:

• syringe material;
• stopper and plunger elastomer;
• oxygen exposure;
• light transmission;
• temperature excursions;
• freezing risk;
• dilution stability;
• compatibility with common infusion fluids.

Any stability extension must be demonstrated in the final marketed container, not inferred from bulk solution data. The opportunity is commercially meaningful because hospital pharmacies often discard compounded cytotoxic doses when treatment schedules change.

What formulation patents protect Vincasar PFS?

Vincasar PFS has limited apparent patent differentiation. Vincristine sulfate is an old active pharmaceutical ingredient, and the product’s commercial value is not primarily protected by a new molecular entity patent.

Potential intellectual-property positions may involve:

• prefilled syringe architecture;
• drug-device combinations;
• hazardous-drug handling systems;
• container-closure designs;
• automated dose preparation;
• stability-enhancing packaging;
• manufacturing and filling processes.

These rights would generally be narrower than a composition-of-matter patent and could be designed around by competitors using a different syringe, package, or preparation process.

A formulation patent would need to claim a measurable advantage, such as improved stability, reduced adsorption, reduced extractables, or a specific container configuration. A claim directed only to sodium chloride, water for injection, and pH adjustment would face significant novelty and obviousness challenges given the established nature of vincristine injectable formulations.

When does Vincasar PFS lose exclusivity?

Vincasar PFS does not depend on a contemporary patent cliff. Vincristine sulfate has been marketed for decades, and generic injectable vincristine products have existed for many years. The relevant competitive event is therefore continued generic substitution and contract purchasing, not the expiration of a single current patent.

Exclusivity category	Vincasar PFS assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the principal protection for the marketed product
Pediatric exclusivity	No current commercial significance
Composition-of-matter patent	No meaningful current protection expected for vincristine sulfate
Formulation patent	Any protection would likely be narrow and presentation-specific
Orange Book patent barrier	No major current barrier is evident from the mature product profile
Generic entry	Already established
Biosimilar risk	Not applicable; vincristine is a small-molecule drug

FDA generic approval generally proceeds through an abbreviated new drug application. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable injectable-product requirements. It does not need to reproduce the branded product’s commercial packaging unless that packaging is necessary to meet an approved product specification.

What is the Orange Book status of Vincasar PFS?

The FDA Orange Book is the relevant source for approved drug products, therapeutic equivalence evaluations, and listed patents. For a mature vincristine sulfate injection, the strategic issue is whether any unexpired listed patent or regulatory exclusivity blocks ANDA approval.

The principal business conclusion is that Orange Book status is unlikely to provide durable protection for the core vincristine sulfate injectable formulation. Any surviving protection would more likely relate to a specific presentation, method of use, or device component than to the active ingredient itself.[2]

Paragraph IV litigation risk is consequently limited for the basic product but could arise if a sponsor listed a later-developed formulation or device patent. A generic applicant challenging such a patent could file a Paragraph IV certification and trigger patent litigation under the Hatch-Waxman framework. The absence of a strong core patent estate makes commercial execution more important than litigation positioning.

What FDA regulatory issues affect Vincasar PFS commercialization?

The key regulatory issues are safety, route control, sterile manufacturing, and hazardous-drug handling.

FDA labeling emphasizes the following:

• intravenous administration only;
• fatal risk from intrathecal administration;
• dosing based on patient-specific clinical factors;
• careful handling by trained personnel;
• monitoring for neurotoxicity, myelosuppression, and other adverse effects;
• protection from inappropriate administration routes.

A new presentation would likely require regulatory support for:

1. container-closure integrity;
2. sterility assurance;
3. particulate limits;
4. extractables and leachables;
5. stability under labeled storage conditions;
6. dose accuracy;
7. compatibility with administration systems;
8. human-factors review if the package or labeling changes route-control safeguards.

A ready-to-administer product can reduce preparation burden, but it can also increase the consequences of selection errors if syringes for different vinca alkaloids look similar. Color coding, barcode controls, auxiliary warnings, and physical separation in inventory are important commercial design elements.

What generic entry risks exist for Vincasar PFS?

The largest risk is price-based substitution by conventional vincristine sulfate vials. Generic manufacturers can compete with lower-cost vial presentations, particularly in hospital tenders and group purchasing organization contracts.

The main generic risks are:

Risk	Effect on Vincasar PFS
Lower-cost vial	Pressures unit price
Multiple generic suppliers	Reduces switching costs
Hospital contract rebid	Can remove formulary preference
Drug-shortage volatility	Can increase demand temporarily but undermine predictable supply
Compounded alternatives	May substitute when supply is constrained
Similar prefilled products	Erodes presentation differentiation
Wholesaler inventory preference	Limits access despite clinical demand

Vincasar PFS can defend against this pressure through total-cost-of-use arguments. Those arguments must be quantified. Relevant measures include pharmacy preparation time, hazardous-drug exposure events, discarded doses, medication errors, inventory turns, and administration delays.

How strong is the Vincasar PFS patent estate?

The core patent estate is weak relative to newer oncology products because the active ingredient and basic injectable formulation are old. The commercial estate can still be strengthened through a layered strategy.

Core product layer

This layer covers vincristine sulfate in an aqueous injectable solution. It is difficult to protect broadly because similar products are established.

Device layer

This layer can cover a prefilled syringe, connector, plunger, needle-free interface, or dose-control feature. Device patents may provide useful differentiation but usually have narrower infringement scope.

Packaging layer

Light-protective, tamper-evident, barcode-integrated, or hazardous-drug-specific packaging can support design protection and potentially utility-patent claims.

Process layer

A sponsor could pursue claims directed to filling, sterilization, low-shear processing, oxygen control, or improved syringe assembly. Process patents are commercially useful only if competitors would need to use the claimed process.

Service and procurement layer

Hospital inventory integration, automated dispensing, dose banding, and electronic traceability are commercial advantages but may be difficult to protect as strong pharmaceutical patents. They are better treated as operating-system and contracting advantages.

Which companies are competing with Vincasar PFS?

Competition comes from several groups:

• manufacturers of generic vincristine sulfate injection;
• suppliers of conventional single-dose vials;
• hospital pharmacies that compound or prepare doses internally;
• oncology distributors and specialty wholesalers;
• manufacturers of closed-system transfer and hazardous-drug handling equipment.

The relevant competitive comparison is not only brand versus generic. It is also prefilled syringe versus vial, outsourced preparation versus in-house preparation, and premium supply reliability versus lowest acquisition cost.

Vincasar PFS has a stronger position in institutions that value ready-to-administer products and standardized hazardous-drug workflows. Conventional vials remain stronger where procurement is driven primarily by price.

What licensing deals could create commercial value?

The most credible licensing opportunities involve delivery and workflow partners rather than a new excipient owner.

Potential partners include:

• syringe and primary-container manufacturers;
• closed-system transfer device companies;
• oncology pharmacy automation suppliers;
• contract manufacturers with sterile filling capacity;
• specialty distributors;
• group purchasing organizations;
• electronic medication administration and barcode vendors.

A licensing deal could combine Vincasar PFS with a validated connector or pharmacy workflow. The agreement should define responsibility for device compatibility, post-approval changes, quality complaints, recalls, and pharmacovigilance.

An excipient supplier would have limited leverage unless it can demonstrate a material benefit, such as extended stability, reduced adsorption, or improved compatibility with a specific administration device.

What revenue exposure does Vincasar PFS have?

Public financial reporting generally does not isolate Vincasar PFS revenue from broader oncology or generic pharmaceutical sales. A product-specific revenue estimate therefore cannot be derived reliably from public company disclosures.

Revenue exposure depends on:

• hospital and group purchasing contracts;
• supply availability;
• generic price erosion;
• prefilled syringe adoption;
• oncology treatment volumes;
• pediatric and adult utilization;
• distributor stocking behavior;
• supply continuity during generic shortages.

The product’s commercial upside is more likely to come from share capture and margin preservation than from market expansion. Vincristine is an established therapy with a defined clinical role. A supplier that improves availability and reduces preparation burden can command a premium in selected accounts, but broad price premiums will be difficult to sustain without validated workflow savings.

What is the best commercial strategy for Vincasar PFS?

The strongest strategy is a differentiated injectable platform with five elements:

1. Preserve the simple sodium chloride and water-for-injection formulation.
2. Invest in syringe, connector, and light-protective packaging performance.
3. Offer a controlled number of standardized dose presentations.
4. Generate hospital data on preparation time, waste, and safety.
5. Use supply reliability and workflow integration to defend pricing.

A new excipient should be pursued only if it produces a clear, label-supported benefit. Otherwise, formulation complexity would add development and manufacturing risk without creating durable competitive protection.

Key Takeaways

• Vincasar PFS uses a minimal, preservative-free aqueous formulation centered on sodium chloride and water for injection.
• The product’s strongest differentiation is its ready-to-use prefilled syringe presentation.
• Core patent protection is limited because vincristine sulfate and basic injectable formulations are long-established.
• Biosimilar competition does not apply; generic injectable competition does.
• The best commercial opportunities involve low-dead-volume syringes, closed-system compatibility, light protection, dose standardization, and stability improvements.
• New excipients are less attractive than packaging and device innovations.
• FDA regulatory value is concentrated in sterile assurance, container compatibility, route-control labeling, and hazardous-drug handling.
• Revenue growth is more likely to result from hospital workflow value and supply reliability than from therapeutic market expansion.

FAQs

Is Vincasar PFS preservative-free?

Yes. Vincasar PFS is labeled as a preservative-free vincristine sulfate injection. Its inactive ingredients are limited to sodium chloride, water for injection, and pH-adjusting agents.[1]

Can Vincasar PFS be administered intrathecally?

No. Vincristine products are for intravenous administration only. Intrathecal administration is associated with a fatal medication error risk and is expressly prohibited in the prescribing information.[1]

Is Vincasar PFS a biologic that can face biosimilar competition?

No. Vincristine sulfate is a small-molecule drug. Competition proceeds through generic-drug pathways rather than biosimilar approval pathways.

Can a new excipient create patent protection for Vincasar PFS?

Only if the excipient produces a novel, non-obvious, and demonstrable formulation benefit. Broad protection for a conventional aqueous vincristine sulfate injection would face substantial prior-art limitations.

What is the highest-value development program for Vincasar PFS?

A validated ready-to-administer platform combining syringe compatibility, low residual volume, light protection, barcode-enabled labeling, and closed-system transfer compatibility is likely to offer more commercial value than a new solution excipient.

References

1. U.S. Food and Drug Administration. (2024). Vincasar PFS: Vincristine sulfate injection, prescribing information. Teva Pharmaceuticals USA, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings, 2023. Centers for Disease Control and Prevention.

5. U.S. Pharmacopeia. (2023). General chapter <800>: Hazardous drugs: Handling in healthcare settings. United States Pharmacopeial Convention.